Cambridge Healthtech Institute’s 7th Annual

Next Generation Cell-Based Immunotherapies

Advances in CARs, TILs, and TCRs

21-22 June 2023

Initial good responses to T cell therapies can be followed by rapid relapse owing to tumour-related mutations and evasion mechanisms put out by the tumour. Despite these challenges, these treatments are reaching the clinic and showing benefit to the patient, often when applied in combination or with co-stimulation. What learnings can be gleaned from the first-generation T cell therapies, and how can we apply them to next-generation CARs, TILs and TCRs, targeting NK, gamma-delta, and other macrophage or myeloid cells? The Next-Generation Cell-Based Immunotherapies conference will explore the advances in engineering, in vivo and ex vivo approaches, allosteric and allogeneic platforms, preclinical to clinical updates, and the latest efforts toward solid tumours.

Coverage will include, but is not limited to:

New Era of CAR Cell Therapies

CAR-NK
CAR-M
CAR-GDT
CAR-iPSC
Armored CAR T cells

Next Generation TILs and TCRs
Novel Engineering and Delivery Technologies in Cell Therapies
Advances in Allogeneic Cell Therapies
Clinical Updates
- Targeting Solid Tumors
- Dual antigen targeting
- Novel Targets

The deadline for priority consideration is 2 December 2022.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: